Having trouble accessing articles? Reset your cache.

CMV bivalent vaccine: Final Phase II data

Final data from a double-blind, U.S. Phase II trial in 74 CMV-seropositive hematopoietic stem cell transplant recipients showed that TransVax significantly increased T cell responses to phosphoprotein 65 CMV

Read the full 292 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE